New study reveals "enormous medical value" of Lundbeck's new migraine drug compared to generics, Head of R&D says

Lundbeck's migraine treatment Vyepti is more expensive than traditional treatment options, which are available as generic drugs, but EVP and Head of R&D Johan Luthman says recently publicized phase III data supports the pricing assessment for the drug.

Photo: PR / Lundbeck

Lundbeck's newest study of migraine therapy vyepti will not result in new indications for the drug or expand the enclosed patient information leaflet in any major way. Nonetheless, Head of Research and Development at Lundbeck Johan Luthman is pleased about the results.

"It's not a registration study per say, and so it's not required, but it is as important as any pivotal study because it adds a lot of very important information on the drug," he tells MedWatch, adding:

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs